DexCom, Inc. (NASDAQ:DXCM – Get Free Report) fell 4.4% during trading on Wednesday after Stifel Nicolaus lowered their price target on the stock from $155.00 to $145.00. Stifel Nicolaus currently has a buy rating on the stock. DexCom traded as low as $81.23 and last traded at $81.50. 768,855 shares changed hands during trading, a decline of 74% from the average session volume of 3,014,919 shares. The stock had previously closed at $85.21.
A number of other equities research analysts also recently issued reports on DXCM. Canaccord Genuity Group increased their price target on shares of DexCom from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, July 28th. StockNews.com began coverage on shares of DexCom in a report on Thursday, October 5th. They issued a “hold” rating on the stock. Citigroup lowered their price target on shares of DexCom from $150.00 to $115.00 in a report on Monday, October 2nd. Oppenheimer increased their price target on shares of DexCom from $135.00 to $150.00 in a report on Friday, July 28th. Finally, BTIG Research raised their target price on shares of DexCom from $134.00 to $150.00 in a research note on Monday, June 26th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $132.38.
Insider Activity at DexCom
In related news, Director Steven Robert Pacelli sold 412 shares of DexCom stock in a transaction on Monday, July 24th. The shares were sold at an average price of $130.58, for a total value of $53,798.96. Following the sale, the director now owns 126,419 shares in the company, valued at $16,507,793.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Steven Robert Pacelli sold 412 shares of DexCom stock in a transaction on Monday, July 24th. The shares were sold at an average price of $130.58, for a total value of $53,798.96. Following the sale, the director now owns 126,419 shares in the company, valued at $16,507,793.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jereme M. Sylvain sold 1,844 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $104.38, for a total value of $192,476.72. Following the transaction, the chief financial officer now directly owns 72,867 shares of the company’s stock, valued at approximately $7,605,857.46. The disclosure for this sale can be found here. Insiders have sold a total of 10,157 shares of company stock worth $1,225,378 over the last quarter. Corporate insiders own 0.41% of the company’s stock.
Hedge Funds Weigh In On DexCom
Several large investors have recently modified their holdings of DXCM. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of DexCom by 141,272.2% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 47,321,524 shares of the medical device company’s stock worth $6,081,289,000 after purchasing an additional 47,288,051 shares during the last quarter. Norges Bank bought a new stake in DexCom in the 4th quarter worth about $421,378,000. 1832 Asset Management L.P. bought a new stake in DexCom in the 4th quarter worth about $151,538,000. Clearbridge Investments LLC increased its holdings in DexCom by 304.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock worth $674,329,000 after buying an additional 992,049 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in DexCom by 287.6% in the 1st quarter. Thrivent Financial for Lutherans now owns 846,632 shares of the medical device company’s stock worth $98,362,000 after buying an additional 628,201 shares in the last quarter. Hedge funds and other institutional investors own 93.88% of the company’s stock.
DexCom Price Performance
The firm has a fifty day moving average of $101.38 and a 200 day moving average of $115.28. The company has a market capitalization of $31.39 billion, a P/E ratio of 99.08, a P/E/G ratio of 1.57 and a beta of 1.13. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 1.16.
DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.12. The company had revenue of $871.30 million during the quarter, compared to the consensus estimate of $841.16 million. DexCom had a return on equity of 22.01% and a net margin of 11.18%. The firm’s revenue was up 25.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.17 EPS. On average, equities research analysts anticipate that DexCom, Inc. will post 1.23 EPS for the current year.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.